<DOC>
	<DOCNO>NCT00307541</DOCNO>
	<brief_summary>Evaluate immune response GSK Biologicals ' 10-valent pneumococcal conjugate vaccine one month completion 3-dose primary vaccination course administer 2 , 3 , 4 month age</brief_summary>
	<brief_title>Assess Immunogenicity GSK Biologicals ' 10-valent Pneumococcal Conjugate Vaccine</brief_title>
	<detailed_description>Test group : 2 group ( 60 subjects/group ) . 10Pn-PD-DiT group receive GSK Biologicals ' 10-valent pneumococcal conjugate vaccine + DTPa-HBV-IPV/Hib ; Control group receive Prevenar + DTPa-HBV-IPV/Hib</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : Male female , include , 8 16 week ( 56118 day ) age time first vaccination , free obvious health problem write informed consent obtain parent/guardian subject . Exclusion criterion : Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . Planned administration/ administration license vaccine foreseen study protocol period start one month first dose vaccine ( ) entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>